Corium International Inc  

(Public, NASDAQ:CORI)   Watch this stock  
Find more results for CORI
7.02
-0.24 (-3.31%)
Jan 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.50 - 7.35
52 week 4.30 - 8.49
Open 7.06
Vol / Avg. 0.00/17,859.00
Mkt cap 129.21M
P/E     -
Div/yield     -
EPS -0.55
Shares 18.07M
Beta     -
Inst. own 87%
Nov 17, 2014
Q4 2014 Corium International Inc Earnings Call
Nov 17, 2014
Q4 2014 Corium International Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2014
Net profit margin -57.51% -23.36%
Operating margin -43.33% -23.68%
EBITD margin - -17.40%
Return on average assets -36.31% -18.06%
Return on average equity -174.49% -
Employees 243 -
CDP Score - -

Address

235 Constitution Dr
MENLO PARK, CA 94025-1108
United States - Map
+1-650-2988012 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage its broad experience in transdermal and transmucosal delivery systems. The Company´┐Żs marketed products are Clonidine Transdermal Delivery System, or TDS, Fentanyl TDS and four Crest Advanced Seal Whitestrips products. Its transdermal technologies are MicroCor, a biodegradable microstructure patch technology for active delivery of proteins, peptides and vaccines large molecules that require active transport through the skin, and Corplex, a novel adhesive system and patch technology for delivery of small molecules that may otherwise be difficult to formulate and deliver.

Officers and directors

Peter D. Staple President & CEO
Age: 62
Bio & Compensation  - Reuters
Robert Breuil Chief Financial Officer
Bio & Compensation  - Reuters
Tim Sweemer Chief Accounting Officer
Bio & Compensation  - Reuters
Christina Dickerson Vice President, Corporate Development
Bio & Compensation  - Reuters
Bobby Singh Ph.D. Vice President, Research & Development
Bio & Compensation  - Reuters
Ivan P. Gergel M.D. Director
Age: 52
Bio & Compensation  - Reuters
Paul Goddard Ph.D. Director
Bio & Compensation  - Reuters